Swedish Neuroscience Institute leads national ultrasound technology research
FOR IMMEDIATE RELEASE
Contact: Clay Holtzman, Swedish, (206) 998-5028, email@example.comSEATTLE — July 30, 2014 — The Swedish Neuroscience Institute (SNI) is expanding its study of focused ultrasound as a novel treatment for brain disorders with the opening of two clinical trials examining the treatment of Parkinson’s disease and brain tumors. The new trials add to the institute’s ongoing study of focused ultrasound for a treatment of essential tremor (ET).
“SNI is one of the few locations in the world where focused ultrasound is being studied at this level. These efforts exemplify SNI’s ongoing mission to deliver leading edge treatment for brain and spinal conditions,” said David Newell, M.D., Chief of Neurosciences at SNI. “We are honored to be a pioneer in this field and are eager to produce translational results.”
These trials come after SNI launched a study last year examining focused ultrasound’s potential as a treatment for essential tremor, a common neurological disorder resulting in involuntary shaking. The original study was designed to determine viability and safety of ultrasound treatment in improving the quality of life for those affected. Together, these three studies place SNI at the forefront of clinical care providers studying focused ultrasound as a treatment approach.